IL279186A - Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts - Google Patents

Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts

Info

Publication number
IL279186A
IL279186A IL279186A IL27918620A IL279186A IL 279186 A IL279186 A IL 279186A IL 279186 A IL279186 A IL 279186A IL 27918620 A IL27918620 A IL 27918620A IL 279186 A IL279186 A IL 279186A
Authority
IL
Israel
Prior art keywords
acetylpyridin
thiazolidine
dione
ethoxy
benzyl
Prior art date
Application number
IL279186A
Other languages
English (en)
Hebrew (he)
Inventor
Collazo Ana Maria Garcia
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Lopez Estefania Traver
De La Cruz Moreno Maria Angeles Perez
Original Assignee
Minoryx Therapeutics S L
Collazo Ana Maria Garcia
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Lopez Estefania Traver
De La Cruz Moreno Maria Angeles Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L, Collazo Ana Maria Garcia, Pedemonte Marc Martinell, Lalanza Maria Pilar Pizcueta, Lopez Estefania Traver, De La Cruz Moreno Maria Angeles Perez filed Critical Minoryx Therapeutics S L
Publication of IL279186A publication Critical patent/IL279186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL279186A 2018-06-06 2020-12-03 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts IL279186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382402 2018-06-06
PCT/IB2019/054744 WO2019234690A1 (en) 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Publications (1)

Publication Number Publication Date
IL279186A true IL279186A (en) 2021-01-31

Family

ID=62716011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279186A IL279186A (en) 2018-06-06 2020-12-03 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts

Country Status (14)

Country Link
US (2) US20210228558A1 (https=)
EP (1) EP3801517A1 (https=)
JP (1) JP7510170B2 (https=)
KR (1) KR20210031867A (https=)
CN (1) CN112823004A (https=)
AU (1) AU2019283650A1 (https=)
BR (1) BR112020024939A2 (https=)
CA (1) CA3102584A1 (https=)
CL (1) CL2020003163A1 (https=)
EA (1) EA202092954A1 (https=)
IL (1) IL279186A (https=)
MX (1) MX2020013182A (https=)
SG (1) SG11202012095XA (https=)
WO (1) WO2019234690A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
FI3801515T3 (fi) 2018-06-06 2025-05-27 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
EP4142720A1 (en) * 2020-04-30 2023-03-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
CN117769418A (zh) * 2021-05-19 2024-03-26 爱博利瓦有限公司 Kl1333用于医疗
MX2025013233A (es) * 2023-05-09 2026-02-03 Minoryx Therapeutics S L Formas polimorficas y formulaciones de leriglitazona

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639229B2 (en) 1992-04-30 2009-11-25 Institut Pasteur Rapid detection of antibiotic resistance in mycobacterium tuberculosis
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
AU2012203941A1 (en) * 2006-06-27 2012-07-26 Sandoz Ag New method for salt preparation
WO2008000418A2 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3125888B1 (en) 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Also Published As

Publication number Publication date
EP3801517A1 (en) 2021-04-14
MX2020013182A (es) 2021-02-26
CN112823004A (zh) 2021-05-18
KR20210031867A (ko) 2021-03-23
JP7510170B2 (ja) 2024-07-03
CA3102584A1 (en) 2019-12-12
SG11202012095XA (en) 2021-01-28
WO2019234690A1 (en) 2019-12-12
US20240091210A1 (en) 2024-03-21
JP2021527061A (ja) 2021-10-11
BR112020024939A2 (pt) 2021-03-09
US20210228558A1 (en) 2021-07-29
AU2019283650A1 (en) 2021-01-07
CL2020003163A1 (es) 2021-07-02
EA202092954A1 (ru) 2021-04-08

Similar Documents

Publication Publication Date Title
IL279186A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts
FI3511319T3 (fi) Lysiinispesifisen demetylaasi-1:n inhibiittoreita
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
IL265298B (en) History of 5-[2-(pyridin-2-ylamino)-3,1-thiazol-5-yl]-3,2,dihydro-1 h -isoindol-1-one and their use as dual inhibitors of phosphatidylinositol 3-kinase delta and gamma
PL3873884T3 (pl) Pochodne 3-(chinolin-8-ylo)-1,4-dihydropirydo[3,4-d]pirymidyno-2,4-dionu jako inhibitory integryny alfa4beta7 do leczenia chorób zapalnych
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
ZA201408734B (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
SI3801515T1 (sl) 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni
WO2012036919A3 (en) Combination of braf and vegf inhibitors
HK40049678A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
MX2022013021A (es) Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
SI3019497T1 (sl) Nova sol 3-((3-((4-(4-morfolinilmetil)-1h-pirol-2-il)metilen)-2-okso- 2,3-dihidro-1h-indol-5-il)metil)-1,3-tiazolidin-2,4-diona, njen sestavek in formulacije, ki jo vsebujejo
IL257232A (en) Linkage between 3-[(3-{[4-(4-morpholinylmethyl)-h1-pyrrol-2-yl)methylene}-2-oxo-3,2-dihydro-h1-indol-5-yl)methyl]- 3,1-thiazolidine-4,2-dione and egfr tyrosine kinase inhibitor
MY179339A (en) Crystal of azole benzene derivative
PL385697A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2, 4-tiazolidynodionu z kwasem 1, 5-naftalenodisulfonowym i sposób jej wytwarzania
EP3909952A4 (en) SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF
PT2602258E (pt) Monohidrato de mesilato de n-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida